Generic Altreno Availability
Last updated on Apr 10, 2025.
Altreno is a brand name of tretinoin topical, approved by the FDA in the following formulation(s):
ALTRENO (tretinoin - lotion;topical)
-
Manufacturer: DOW PHARM
Approval date: August 23, 2018
Strength(s): 0.05% [RLD]
Is there a generic version of Altreno available?
No. There is currently no therapeutically equivalent version of Altreno available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Altreno. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Topical pharmaceutical compositions for treating skin conditions
Patent 10,653,656
Issued: May 19, 2020
Inventor(s): Bhatt Varsha & Pillai Radhakrishnan
Assignee(s): Bausch Health Ireland LimitedIn one aspect, topical pharmaceutical compositions for treating a skin condition or disorder are provided. In some embodiments, the topical pharmaceutical composition is formulated as a lotion and comprises a therapeutically effective amount of an active agent; a viscosity increasing agent; a polymeric emulsifier; and an oil component. In some embodiments, the topical pharmaceutical composition comprises tretinoin.
Patent expiration dates:
- August 22, 2038✓✓
- August 22, 2038
-
Topical pharmaceutical compositions for treating skin conditions
Patent 11,324,710
Issued: May 10, 2022
Inventor(s): Bhatt; Varsha et al.
Assignee(s): BAUSCH HEALTH IRELAND LIMITED (Dublin, IE)Topical pharmaceutical compositions for treating a skin condition or disorder are provided. The topical pharmaceutical compositions can be formulated as lotions containing a therapeutically effective amount of an active agent, such as tretinoin, a viscosity increasing agent, and advantageously small amounts of both a polymeric emulsifier and an oil component. The topical compositions of the present invention are tolerated exceptionally well by subjects to whom the compositions are administered.
Patent expiration dates:
- August 22, 2038✓
- August 22, 2038
More about Altreno (tretinoin topical)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: topical acne agents
- Breastfeeding
- En español
Patient resources
Other brands
Retin-A, Atralin, Renova, Avita, ... +2 more
Professional resources
Other brands
Retin-A, Atralin, Renova, Avita, Refissa
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.